Pub Date : 2024-10-09DOI: 10.1016/j.ad.2024.10.008
D Martín-Torregrosa, M Mansilla-Polo, D Morgado-Carrasco
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.
Anifrolumab 是一种 I 型干扰素受体亚基 1（IFNAR1）抑制剂，最近被批准用于治疗中重度系统性红斑狼疮（SLE）。在两项临床试验中，它被证明能有效治疗皮肤症状。尽管阿尼单抗尚未用于治疗皮肤红斑狼疮（CLE），但多个病例和病例系列（20 篇文献，共 78 名患者）显示，无论是亚急性皮肤红斑狼疮和盘状红斑狼疮，还是狼疮泛发性皮炎和牛皮癣，使用这种药物都能产生良好而快速的反应。两份皮肌炎病例报告也显示，使用阿尼洛单抗后临床症状有所改善。针对亚急性CLE和盘状红斑狼疮、系统性硬化症和进行性白癜风的临床试验正在进行中。该药最常见的不良反应是呼吸道感染和带状疱疹。阿尼单抗可能是一种耐受性良好的治疗 CLE 的替代药物。
{"title":"[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.","authors":"D Martín-Torregrosa, M Mansilla-Polo, D Morgado-Carrasco","doi":"10.1016/j.ad.2024.10.008","DOIUrl":"10.1016/j.ad.2024.10.008","url":null,"abstract":"<p><p>Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-09DOI: 10.1016/j.ad.2024.10.005
L Cayuela, J J Pereyra-Rodríguez, J C Hernández-Rodríguez, L Rodríguez Fernandez-Freire, A Cayuela
Aim: This study aimed to investigate the effects of age, period, and cohort on the incidence of psoriasis in Spain from 1990 through 2019 using the Global Burden of Disease (GBD) database and age-period-cohort (A-P-C) analysis.
Methods: We conducted an ecological trend study to analyze the incidence rates of psoriasis in Spain from 1990 through 2019. Joinpoint Regression Program, Version 5.0.2 - May 2023; Surveillance Research Program, National Cancer Institute and National Cancer Institute A-P-C tools were used to identify trends and assess the effects of age, period, and cohort.
Results: From 1990 through 2019, an estimated 2.99 million cases of psoriasis were diagnosed in Spain, with a mean annual increase of 0.49%. Significant decreases in age-standardized incidence rates (ASIR) were reported for both sexes, with women consistently maintaining a slightly higher ASIR. Joinpoint analysis revealed multiple turning points in the downward trend, indicating periods of stabilization. A-P-C analysis demonstrated significant declines in both net (overall trend) and local drift (age-specific trends), indicating a broad decrease in the incidence of psoriasis across most age groups. While the risk of psoriasis increased with age, peaking in the 50-54 age group, it declined thereafter. Furthermore, the analysis revealed a continuous decline in risk from 1990 through 2019 for both sexes, with individuals born in the early 21st century exhibiting a significantly lower risk vs those born in the early 20th century.
Conclusion: This study observed a slight decline in the reported psoriasis ASIR in Spain, potentially due to reduced exposure to risk factors. However, limitations in data and the complexity of factors influencing the incidence of psoriasis require further research.
{"title":"Effects of Age, Period, and Cohort on the Incidence of Psoriasis in Spain: A 30-year Review (1990-2019).","authors":"L Cayuela, J J Pereyra-Rodríguez, J C Hernández-Rodríguez, L Rodríguez Fernandez-Freire, A Cayuela","doi":"10.1016/j.ad.2024.10.005","DOIUrl":"10.1016/j.ad.2024.10.005","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the effects of age, period, and cohort on the incidence of psoriasis in Spain from 1990 through 2019 using the Global Burden of Disease (GBD) database and age-period-cohort (A-P-C) analysis.</p><p><strong>Methods: </strong>We conducted an ecological trend study to analyze the incidence rates of psoriasis in Spain from 1990 through 2019. Joinpoint Regression Program, Version 5.0.2 - May 2023; Surveillance Research Program, National Cancer Institute and National Cancer Institute A-P-C tools were used to identify trends and assess the effects of age, period, and cohort.</p><p><strong>Results: </strong>From 1990 through 2019, an estimated 2.99 million cases of psoriasis were diagnosed in Spain, with a mean annual increase of 0.49%. Significant decreases in age-standardized incidence rates (ASIR) were reported for both sexes, with women consistently maintaining a slightly higher ASIR. Joinpoint analysis revealed multiple turning points in the downward trend, indicating periods of stabilization. A-P-C analysis demonstrated significant declines in both net (overall trend) and local drift (age-specific trends), indicating a broad decrease in the incidence of psoriasis across most age groups. While the risk of psoriasis increased with age, peaking in the 50-54 age group, it declined thereafter. Furthermore, the analysis revealed a continuous decline in risk from 1990 through 2019 for both sexes, with individuals born in the early 21st century exhibiting a significantly lower risk vs those born in the early 20th century.</p><p><strong>Conclusion: </strong>This study observed a slight decline in the reported psoriasis ASIR in Spain, potentially due to reduced exposure to risk factors. However, limitations in data and the complexity of factors influencing the incidence of psoriasis require further research.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-08DOI: 10.1016/j.ad.2024.10.003
M A Lasheras-Perez, L Puebla-Tornero, J Canueto, B de Unamuno-Bustos, R Botella-Estrada
{"title":"Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.","authors":"M A Lasheras-Perez, L Puebla-Tornero, J Canueto, B de Unamuno-Bustos, R Botella-Estrada","doi":"10.1016/j.ad.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.ad.2024.10.003","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ad.2024.02.018
Background
Alopecia areata (AA) is an autoimmune disease characterized by non-scaring hair loss and preservation of hair follicles. The information available on disease course, and clinical features of AA is scarce worldwide, and almost nonexistent in Colombia.
Objective
To determine the clinical and sociodemographic characteristics of patients diagnosed with AA who presented to a dermatology consultation in five Colombian cities.
Material and methods
This was a retrospective and multicenter study on data from an ongoing National Registry of Alopecia Areata in Colombia (RENAAC) collected in Bogota, Cali, Cartagena, Barranquilla, and Medellin, Colombia from March 2022 through April 2023. Data was recorded in a standardized form by trained physicians. The variables were expressed as measures of central tendency and dispersion, and absolute and relative frequencies.
Results
A total of 562 patients were included, 59.4% of whom were women, aged between 15 and 49 years (63.9%) with a mean disease course of 1.7 years. The most common finding was multiple plaque (53.2%), the predominant AA subtype was patchy (71.4%), and 29.5% of the patients had a past dermatological history, 18.3% had a past endocrinological history, and 8.9% had a past psychiatric history. The treatments most widely used were steroid injections (76.4%), 5% topical minoxidil (46.4%), followed by high-potency corticosteroids (42.5%).
Study limitations and conclusions
AA was slightly predominant in women. As seen in other populations, this disease had an earlier onset in men vs women. Presentation in pediatric age was uncommon. The previous history of other dermatological diseases was checked in almost one third of the patients. Analysis of the co-presentation of AA with other autoimmune diseases is biased due to excluding patients with systemic erythematous lupus from the study.
背景：斑秃（AA）是一种自身免疫性疾病，其特点是脱发不严重，毛囊可保留。全世界有关 AA 病程和临床特征的资料很少，而在哥伦比亚几乎没有：确定哥伦比亚 5 个城市皮肤科就诊的 AA 患者的临床和社会人口特征：这是一项回顾性多中心研究，研究对象是正在进行的哥伦比亚全国脱发登记处（RENAAC）从2022年3月至2023年4月在哥伦比亚波哥大、卡利、卡塔赫纳、巴兰基亚和麦德林收集的数据。数据由经过培训的医生以标准化的形式获取。变量以中心倾向和离散度、绝对频率和相对频率表示：共纳入 562 名患者，其中 59.4% 为女性，年龄在 15 至 49 岁之间（63.9%），平均病程为 1.7 年。最常见的症状是多发性斑块（53.2%），最主要的 AA 亚型是斑片状（71.4%），29.5%的患者有皮肤病史，18.3%的患者有内分泌病史，8.9%的患者有精神病史。使用最多的治疗方法是类固醇注射（76.4%）、5%的局部米诺地尔（46.4%），其次是高效皮质类固醇激素（42.5%）。研究局限和结论：女性患者中 AA 略占多数。正如在其他人群中看到的那样，这种疾病在男性和女性中发病较早。儿童发病并不常见。近三分之一的患者曾患其他皮肤病。由于研究排除了系统性红斑狼疮患者，因此对AA与其他自身免疫性疾病的共同表现的分析存在偏差。
{"title":"Clinical and Sociodemographic Features of Alopecia Areata in Five Colombian Cities: An Analysis of the RENAAC Registry","authors":"","doi":"10.1016/j.ad.2024.02.018","DOIUrl":"10.1016/j.ad.2024.02.018","url":null,"abstract":"<div><h3>Background</h3><div>Alopecia areata (AA) is an autoimmune disease characterized by non-scaring hair loss and preservation of hair follicles. The information available on disease course, and clinical features of AA is scarce worldwide, and almost nonexistent in Colombia.</div></div><div><h3>Objective</h3><div>To determine the clinical and sociodemographic characteristics of patients diagnosed with AA who presented to a dermatology consultation in five Colombian cities.</div></div><div><h3>Material and methods</h3><div>This was a retrospective and multicenter study on data from an ongoing National Registry of Alopecia Areata in Colombia (RENAAC) collected in Bogota, Cali, Cartagena, Barranquilla, and Medellin, Colombia from March 2022 through April 2023. Data was recorded in a standardized form by trained physicians. The variables were expressed as measures of central tendency and dispersion, and absolute and relative frequencies.</div></div><div><h3>Results</h3><div>A total of 562 patients were included, 59.4% of whom were women, aged between 15 and 49 years (63.9%) with a mean disease course of 1.7 years. The most common finding was multiple plaque (53.2%), the predominant AA subtype was patchy (71.4%), and 29.5% of the patients had a past dermatological history, 18.3% had a past endocrinological history, and 8.9% had a past psychiatric history. The treatments most widely used were steroid injections (76.4%), 5% topical minoxidil (46.4%), followed by high-potency corticosteroids (42.5%).</div></div><div><h3>Study limitations and conclusions</h3><div>AA was slightly predominant in women. As seen in other populations, this disease had an earlier onset in men vs women. Presentation in pediatric age was uncommon. The previous history of other dermatological diseases was checked in almost one third of the patients. Analysis of the co-presentation of AA with other autoimmune diseases is biased due to excluding patients with systemic erythematous lupus from the study.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139939349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ad.2024.08.005
M.A. Lasheras-Pérez , R. Taberner , B. Martínez-Jarreta
Both the functions and equipment of dermatologists have increased over the past few years, some examples being cosmetic dermatology, artificial intelligence, tele-dermatology, and social media, which added to the pharmaceutical industry and cosmetic selling has become a source of bioethical conflicts. The objective of this narrative review is to identify the bioethical conflicts of everyday dermatology practice and highlight the proposed solutions. Therefore, we conducted searches across PubMed, Web of Science and Scopus databases. Also, the main Spanish and American deontological codes of physicians and dermatologists have been revised. The authors recommend declaring all conflicts of interest while respecting the patients’ autonomy, confidentiality, and privacy. Cosmetic dermatology, cosmetic selling, artificial intelligence, tele-dermatology, and social media are feasible as long as the same standards of conventional dermatology are applied. Nonetheless, the deontological codes associated with these innovations need to be refurbished.
在过去的几年中，皮肤科医生的职能和设备都在不断增加，例如美容皮肤科、人工智能、远程皮肤科和社交媒体，这些都是制药业和化妆品销售的补充，成为生物伦理冲突的根源。本叙事性综述旨在确定日常皮肤病学实践中的生物伦理冲突，并强调建议的解决方案。因此，我们在 PubMed、Web of Science 和 Scopus 数据库中进行了检索。此外，我们还修订了西班牙和美国医生和皮肤科医生的主要伦理守则。作者建议在尊重患者自主权、保密性和隐私权的同时，申报所有利益冲突。只要采用与传统皮肤病学相同的标准，美容皮肤病学、化妆品销售、人工智能、远程皮肤病学和社交媒体都是可行的。然而，与这些创新相关的伦理准则需要重新修订。
{"title":"[Translated article] Bioethical Conflicts in Current Dermatology: A Narrative Review","authors":"M.A. Lasheras-Pérez , R. Taberner , B. Martínez-Jarreta","doi":"10.1016/j.ad.2024.08.005","DOIUrl":"10.1016/j.ad.2024.08.005","url":null,"abstract":"<div><div>Both the functions and equipment of dermatologists have increased over the past few years, some examples being cosmetic dermatology, artificial intelligence, tele-dermatology, and social media, which added to the pharmaceutical industry and cosmetic selling has become a source of bioethical conflicts. The objective of this narrative review is to identify the bioethical conflicts of everyday dermatology practice and highlight the proposed solutions. Therefore, we conducted searches across PubMed, Web of Science and Scopus databases<em>.</em> Also, the main Spanish and American deontological codes of physicians and dermatologists have been revised. The authors recommend declaring all conflicts of interest while respecting the patients’ autonomy, confidentiality, and privacy. Cosmetic dermatology, cosmetic selling, artificial intelligence, tele-dermatology, and social media are feasible as long as the same standards of conventional dermatology are applied. Nonetheless, the deontological codes associated with these innovations need to be refurbished.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ad.2023.02.039
{"title":"Corneal Transplant Rejection and Alopecia Areata Universalis in a Patient With Severe Atopic Dermatitis on Dupilumab","authors":"","doi":"10.1016/j.ad.2023.02.039","DOIUrl":"10.1016/j.ad.2023.02.039","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ad.2024.02.031
Both the functions and equipment of dermatologists have increased over the past few years, some examples being cosmetic dermatology, artificial intelligence, tele-dermatology, and social media, which added to the pharmaceutical industry and cosmetic selling has become a source of bioethical conflicts. The objective of this narrative review is to identify the bioethical conflicts of everyday dermatology practice and highlight the proposed solutions. Therefore, we conducted searches across PubMed, Web of Science and Scopus databases. Also, the main Spanish and American deontological codes of physicians and dermatologists have been revised. The authors recommend declaring all conflicts of interest while respecting the patients’ autonomy, confidentiality, and privacy. Cosmetic dermatology, cosmetic selling, artificial intelligence, tele-dermatology, and social media are feasible as long as the same standards of conventional dermatology are applied. Nonetheless, the deontological codes associated with these innovations need to be refurbished.
在过去的几年中，皮肤科医生的职能和设备都在不断增加，例如美容皮肤科、人工智能、远程皮肤科和社交媒体，这些都是制药业和化妆品销售的补充，成为生物伦理冲突的根源。本叙事性综述旨在确定日常皮肤病学实践中的生物伦理冲突，并强调建议的解决方案。因此，我们在 PubMed、Web of Science 和 Scopus 数据库中进行了检索。此外，我们还修订了西班牙和美国医生和皮肤科医生的主要伦理守则。作者建议在尊重患者自主权、保密性和隐私权的同时，申报所有利益冲突。只要采用与传统皮肤病学相同的标准，美容皮肤病学、化妆品销售、人工智能、远程皮肤病学和社交媒体都是可行的。然而，与这些创新相关的伦理准则需要重新修订。
{"title":"Conflictos bioéticos en la dermatología actual: una revisión narrativa","authors":"","doi":"10.1016/j.ad.2024.02.031","DOIUrl":"10.1016/j.ad.2024.02.031","url":null,"abstract":"<div><div>Both the functions and equipment of dermatologists have increased over the past few years, some examples being cosmetic dermatology, artificial intelligence, tele-dermatology, and social media, which added to the pharmaceutical industry and cosmetic selling has become a source of bioethical conflicts. The objective of this narrative review is to identify the bioethical conflicts of everyday dermatology practice and highlight the proposed solutions. Therefore, we conducted searches across PubMed, Web of Science and Scopus databases<em>.</em> Also, the main Spanish and American deontological codes of physicians and dermatologists have been revised. The authors recommend declaring all conflicts of interest while respecting the patients’ autonomy, confidentiality, and privacy. Cosmetic dermatology, cosmetic selling, artificial intelligence, tele-dermatology, and social media are feasible as long as the same standards of conventional dermatology are applied. Nonetheless, the deontological codes associated with these innovations need to be refurbished.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140331379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号